
USANA Health Sciences USNA
$ 17.19
1.06%
Annual report 2026
added 03-16-2026
USANA Health Sciences Income Statement 2011-2026 | USNA
Annual Income Statement USANA Health Sciences
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
325 M | 335 M | 931 M | 1.18 B | 2.14 B | - | 1.52 B | 2.82 B | 1.87 B | 1.73 B | 1.38 B | - | 841 M | 551 M | 605 M |
Shares |
18.5 M | 19.1 M | 19.2 M | 19.3 M | 21.2 M | - | 22.8 M | 24.6 M | 24.7 M | 26.4 M | 27.4 M | - | 28.4 M | 29.8 M | 31.9 M |
Historical Prices |
17.5 | 17.5 | 48.3 | 61.1 | 101 | 77.1 | 78.5 | 118 | 74 | 61.2 | 63.9 | 51.3 | 37.8 | 16.5 | 15.2 |
Net Income |
10.8 M | 42 M | 63.8 M | 69.4 M | 125 M | - | 101 M | 126 M | 62.5 M | 94.7 M | 76.6 M | - | 79 M | 66.4 M | 45.7 M |
Revenue |
925 M | 855 M | 921 M | 999 M | 1.13 B | - | 1.06 B | 1.19 B | 1.05 B | 918 M | 790 M | - | 718 M | 649 M | 518 M |
Cost of Revenue |
201 M | 161 M | 177 M | 194 M | 209 M | - | 188 M | 201 M | 179 M | 180 M | - | - | - | - | - |
Gross Profit |
724 M | 693 M | 744 M | 805 M | 926 M | - | 873 M | 989 M | 868 M | 759 M | 650 M | - | 591 M | 533 M | 422 M |
Operating Income |
37.4 M | 66.3 M | 93.1 M | 108 M | 176 M | - | 146 M | 188 M | 133 M | 139 M | 116 M | - | 117 M | 98.2 M | 77.3 M |
Interest Expense |
2.52 M | -1.01 M | 7 K | 192 K | 507 K | - | 66 K | 36 K | 46 K | 444 K | 129 K | - | 1 K | 20 K | 9 K |
EBITDA |
70 M | 80.9 M | 106 M | 121 M | 190 M | - | 161 M | 205 M | 149 M | 152 M | 125 M | - | 126 M | 107 M | 76.1 M |
Operating Expenses |
687 M | 627 M | 651 M | 697 M | 749 M | - | 727 M | 800 M | 735 M | 617 M | 534 M | - | 474 M | 435 M | 354 M |
General and Administrative Expenses |
337 M | 263 M | 257 M | 262 M | 261 M | - | 717 M | 791 M | 726 M | 611 M | 528 M | - | 469 M | 430 M | 354 M |
All numbers in USD currency
Quarterly Income Statement USANA Health Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.3 M | 18.5 M | 19 M | 19.1 M | 19.1 M | 19.1 M | 19.2 M | 19.1 M | 19.2 M | 19.3 M | 19.3 M | 19.2 M | 19.2 M | 19.2 M | 19.4 M | 21 M | 20 M | 20.2 M | 20.9 M | - | 21 M | 21 M | 21.5 M | 21.7 M | 22.2 M | 23.2 M | 23.5 M | 23.6 M | 24.3 M | 24.2 M | 24.1 M | 24 M | 24.3 M | 24.6 M | 24.5 M | 24.5 M | 24.2 M | 24 M | 24.2 M | 12.6 M | 12.9 M | 12.7 M | 12.6 M | - | 12.9 M | 13.8 M | 13.9 M | 13.9 M | 13.8 M | 13.5 M | 13.6 M | 13.8 M | 14.4 M | 14.7 M | 15 M | 14.9 M | 15 M | 15.5 M | 15.9 M |
Net Income |
-6.52 M | 9.66 M | 9.4 M | - | 10.6 M | 10.4 M | 16.5 M | - | 11.3 M | 17.3 M | 18.4 M | - | 14.9 M | 19.2 M | 22.5 M | - | 27.3 M | 38.2 M | 30.6 M | - | 30.5 M | 28 M | 26.6 M | 30.8 M | 24.2 M | 21.4 M | 24.2 M | 32.3 M | 31 M | 33.9 M | 28.9 M | -5.85 M | 23.8 M | 23.3 M | 21.4 M | 21.9 M | 30.1 M | 25.8 M | 22.3 M | 21.3 M | 25.6 M | 25.4 M | 19.7 M | - | 19.5 M | 19.3 M | 16.5 M | 20.3 M | 16.8 M | 24.2 M | 17.8 M | 18.4 M | 17.5 M | 16.7 M | 13.8 M | 13.2 M | 12.4 M | 13.9 M | 11.4 M |
Revenue |
214 M | 236 M | 250 M | - | 200 M | 213 M | 228 M | - | 213 M | 238 M | 248 M | - | 233 M | 264 M | 273 M | - | 274 M | 337 M | 308 M | - | 299 M | 259 M | 267 M | 271 M | 261 M | 256 M | 273 M | 299 M | 297 M | 301 M | 292 M | 273 M | 262 M | 257 M | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
48.8 M | 50.2 M | 52.4 M | - | 39.3 M | 40.3 M | 43.1 M | - | 42.5 M | 43.3 M | 48.5 M | - | 46.6 M | 49.5 M | 51.4 M | - | 50.7 M | 57 M | 57.7 M | - | 56.4 M | 47.7 M | 46.1 M | - | 47.8 M | 46.5 M | 45.9 M | - | 51.9 M | 50 M | 49.4 M | - | 47.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
165 M | 186 M | 197 M | - | 161 M | 173 M | 185 M | - | 171 M | 195 M | 200 M | - | 187 M | 215 M | 221 M | - | 224 M | 280 M | 250 M | - | 242 M | 211 M | 221 M | 224 M | 213 M | 210 M | 227 M | 250 M | 245 M | 251 M | 243 M | 227 M | 215 M | 213 M | 213 M | 207 M | 209 M | 213 M | 198 M | 190 M | 192 M | 193 M | 181 M | - | 157 M | 153 M | 149 M | 152 M | 142 M | 157 M | 139 M | 138 M | 135 M | 133 M | 127 M | 121 M | 118 M | 123 M | 118 M |
Operating Income |
1.22 M | 16.7 M | 15.7 M | - | 15.6 M | 17.8 M | 24.7 M | - | 17.6 M | 24.4 M | 26.8 M | - | 22.6 M | 29.4 M | 33.1 M | - | 40.8 M | 53.7 M | 44.2 M | - | 45.4 M | 39.6 M | 39 M | - | 35.5 M | 31.2 M | 35 M | - | 45.5 M | 51.1 M | 43.1 M | - | 31.4 M | 32.4 M | 32.9 M | - | 35.8 M | 37.4 M | 33.5 M | - | 38 M | 38.8 M | 29.8 M | - | 29.3 M | 29.1 M | 25.1 M | - | 24.7 M | 36.5 M | 26.6 M | - | 24.1 M | 25.2 M | 20.9 M | - | 18.8 M | 21.2 M | 17.2 M |
Interest Expense |
41 K | 1.74 M | 756 K | - | -86 K | -349 K | -186 K | - | 234 K | 229 K | 31 K | - | 32 K | 96 K | 32 K | - | 18 K | 16 K | 5 K | - | 1.38 M | 217 K | 21 K | - | 22 K | 10 K | 12 K | - | 8 K | 9 K | 10 K | - | 10 K | 11 K | 10 K | - | 46 K | 176 K | 202 K | - | 4 K | 7 K | 14 K | - | 5 K | 6 K | 6 K | - | -43 K | -164 K | -104 K | - | 11 K | -293 K | 94 K | - | 1 K | 2 K | 6 K |
EBITDA |
9.14 M | 24.5 M | 24 M | - | 19.2 M | 21.7 M | 27.8 M | - | - | - | 30.1 M | - | 32.7 M | 36 M | 36.3 M | - | 50.5 M | 60.2 M | 47.4 M | - | 45.4 M | 39.6 M | 42.5 M | - | 46.6 M | 38.8 M | 38.9 M | - | 58.2 M | 59.8 M | 47.7 M | - | 43.2 M | 40 M | 36.4 M | - | 45.8 M | 44.2 M | 37 M | - | 45.2 M | 43.4 M | 32.1 M | - | 35.9 M | 33.5 M | 27.3 M | - | 31.6 M | 41.1 M | 28.9 M | - | 30.7 M | 29.6 M | 23.1 M | - | 25.1 M | 25.4 M | 19.4 M |
Operating Expenses |
164 M | 169 M | 181 M | - | 145 M | 155 M | 160 M | - | 153 M | 170 M | 173 M | - | 164 M | 186 M | 188 M | - | 183 M | 226 M | 206 M | - | 197 M | 172 M | 182 M | - | 177 M | 178 M | 192 M | - | 199 M | 200 M | 199 M | - | 183 M | 181 M | 180 M | - | 173 M | 175 M | 164 M | - | 154 M | 154 M | 151 M | - | 128 M | 124 M | 123 M | - | 118 M | 121 M | 112 M | - | 111 M | 108 M | 106 M | - | 99.5 M | 102 M | 101 M |
General and Administrative Expenses |
85.9 M | 81.9 M | 91.4 M | - | 61.3 M | 64.3 M | 64.3 M | - | 63.3 M | 68.1 M | 66.9 M | - | 66 M | 66.4 M | 68.8 M | - | 66.6 M | 72.2 M | 71.6 M | - | 65.7 M | 60.9 M | 65.5 M | - | 66.3 M | 66.9 M | 69.6 M | - | 69.1 M | 67.5 M | 70.1 M | - | 67.3 M | 62.4 M | 64 M | - | 60.6 M | 59.8 M | 56.6 M | - | 52.8 M | 52.5 M | 49.9 M | - | 45.5 M | 43.2 M | 44.6 M | - | 41.1 M | 43 M | 42.4 M | - | 40.3 M | 36.8 M | 38 M | - | 33.4 M | 33.8 M | 35.9 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company USANA Health Sciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Household products industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Natura &Co Holding S.A.
NTCO
|
- | - | $ 9.02 B | - | |
|
The Clorox Company
CLX
|
$ 104.76 | 1.64 % | $ 12.9 B | ||
|
Inter Parfums
IPAR
|
$ 91.26 | 1.25 % | $ 2.93 B | ||
|
LifeVantage Corporation
LFVN
|
$ 4.29 | -0.92 % | $ 52.6 M | ||
|
Edgewell Personal Care Company
EPC
|
$ 20.07 | 2.35 % | $ 997 M | ||
|
Mannatech, Incorporated
MTEX
|
$ 6.99 | - | $ 13 M | ||
|
Kimberly-Clark Corporation
KMB
|
$ 99.36 | 0.44 % | $ 33 B | ||
|
Nature's Sunshine Products
NATR
|
$ 23.77 | -0.21 % | $ 428 M | ||
|
Nu Skin Enterprises
NUS
|
$ 7.29 | 1.82 % | $ 359 M | ||
|
Newell Brands
NWL
|
$ 3.56 | 0.28 % | $ 1.49 B | ||
|
Helen of Troy Limited
HELE
|
$ 14.99 | 0.87 % | $ 345 M | ||
|
Coty
COTY
|
$ 2.05 | -0.49 % | $ 1.79 B | ||
|
Church & Dwight Co.
CHD
|
$ 94.38 | 0.54 % | $ 22.9 B | ||
|
The Procter & Gamble Company
PG
|
$ 143.92 | 0.53 % | $ 338 B | ||
|
Revlon
REV
|
- | -4.41 % | $ 212 M | ||
|
Unilever PLC
UL
|
$ 60.8 | 0.3 % | $ 132 B | ||
|
Hims & Hers Health
HIMS
|
$ 20.84 | -2.34 % | $ 4.69 B | ||
|
Spectrum Brands Holdings
SPB
|
- | - | $ 1.94 B | ||
|
Colgate-Palmolive Company
CL
|
$ 85.49 | 1.15 % | $ 69.1 B | ||
|
The Estée Lauder Companies
EL
|
$ 73.11 | 2.28 % | $ 26.3 B | ||
|
United-Guardian
UG
|
$ 6.21 | -0.16 % | $ 28.5 M | ||
|
Dogness (International) Corporation
DOGZ
|
$ 1.51 | 2.03 % | $ 50.9 M | ||
|
e.l.f. Beauty
ELF
|
$ 69.65 | 3.12 % | $ 3.81 B | ||
|
Acme United Corporation
ACU
|
$ 44.43 | 0.18 % | $ 168 M |